Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML)

It is advised that skin examinations should be periodically performed in patients on bendamustine-containing regimens and PML considered in the differential diagnosis for patients on bendamustine with new or worsening neurological, cognitive, or behavioural signs or symptoms.

Source:

Medicines and Healthcare products Regulatory Agency